quavonlimab,lenvatinib,favezelimab,pembrolizumab
eisai,merck
['pembro', 'keynote,495', 'keyimpact', 'impact trial']
#sitc22 | ( ) talks on the biomarker-directed keynote-495/keyimpact trial of pembro-based therapy in #nsclc #oncology #immunoonc #lcsm 